Arcus Biosciences, Inc. (RCUS)

USD 15.17

(-5.66%)

Total Liabilities Summary of Arcus Biosciences, Inc.

Arcus Biosciences, Inc.'s latest annual total liabilities in 2023 was 633 Million USD , down -7.99% from previous year.
Arcus Biosciences, Inc.'s latest quarterly total liabilities in 2024 Q1 was 586 Million USD , down -7.42% from previous quarter.
Arcus Biosciences, Inc. reported annual total liabilities of 688 Million USD in 2022, down -8.32% from previous year.
Arcus Biosciences, Inc. reported annual total liabilities of 750.44 Million USD in 2021, up 177.96% from previous year.
Arcus Biosciences, Inc. reported quarterly total liabilities of 551 Million USD for 2024 Q2, down -5.97% from previous quarter.
Arcus Biosciences, Inc. reported quarterly total liabilities of 671 Million USD for 2023 Q3, up 2.6% from previous quarter.

Annual Total Liabilities Chart of Arcus Biosciences, Inc. (2023 - 2016)

Historical Annual Total Liabilities of Arcus Biosciences, Inc. (2023 - 2016)

Year	Total Liabilities	Total Liabilities Growth
2023	633 Million USD	-7.99%
2022	688 Million USD	-8.32%
2021	750.44 Million USD	177.96%
2020	269.98 Million USD	587.55%
2019	39.26 Million USD	-1.79%
2018	39.98 Million USD	9.19%
2017	36.61 Million USD	257.53%
2016	10.24 Million USD	0.0%

Year	Total Liabilities	Total Liabilities Growth
2024 Q1	586 Million USD	-7.42%
2024 Q2	551 Million USD	-5.97%
2023 Q3	671 Million USD	2.6%
2023 FY	633 Million USD	-7.99%
2023 Q1	654 Million USD	-4.94%
2023 Q2	654 Million USD	0.0%
2023 Q4	633 Million USD	-5.66%
2022 FY	688 Million USD	-8.32%
2022 Q3	695.12 Million USD	-4.7%
2022 Q2	729.38 Million USD	-2.34%
2022 Q4	688 Million USD	-1.02%
2022 Q1	746.84 Million USD	-0.48%
2021 Q2	294.21 Million USD	8.84%
2021 FY	750.44 Million USD	177.96%
2021 Q4	750.44 Million USD	152.95%
2021 Q3	296.68 Million USD	0.84%
2021 Q1	270.32 Million USD	0.13%
2020 FY	269.98 Million USD	587.55%
2020 Q3	266.65 Million USD	406.19%
2020 Q4	269.98 Million USD	1.25%
2020 Q2	52.67 Million USD	48.37%
2020 Q1	35.5 Million USD	-9.58%
2019 Q2	42.32 Million USD	14.51%
2019 FY	39.26 Million USD	-1.79%
2019 Q3	39.73 Million USD	-6.14%
2019 Q1	36.96 Million USD	-7.55%
2019 Q4	39.26 Million USD	-1.16%
2018 Q2	39.29 Million USD	1.24%
2018 FY	39.98 Million USD	9.19%
2018 Q4	39.98 Million USD	-3.89%
2018 Q3	41.6 Million USD	5.88%
2018 Q1	38.8 Million USD	5.98%
2017 Q1	- USD	0.0%
2017 Q4	36.61 Million USD	0.0%
2017 FY	36.61 Million USD	257.53%
2016 FY	10.24 Million USD	0.0%

Peer Total Liabilities Comparison of Arcus Biosciences, Inc.

Name	Total Liabilities	Total Liabilities Difference
ADC Therapeutics SA	503.03 Million USD	-25.837%
Alto Neuroscience, Inc.	158.3 Million USD	-299.874%
Annovis Bio, Inc.	17.95 Million USD	-3424.674%
Biohaven Pharmaceutical Holding Company Ltd.	85.23 Million USD	-642.635%
Ginkgo Bioworks Holdings, Inc.	568.19 Million USD	-11.406%
Nuvation Bio Inc.	16.36 Million USD	-3768.72%
Nuvation Bio Inc.	16.36 Million USD	-3768.72%
Theriva Biologics, Inc.	20.51 Million USD	-2985.698%
Zymeworks Inc.	116.07 Million USD	-445.342%